DISCOUNT-ZERTIFIKAT - ASTRAZENECA | Market Closed - Bid/Ask 15:48:18 2024-05-31 EDT | ||
| 96.85 EUR | +0.14% |
|
| Current month | +0.60% | ||
| 1 month | +0.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 96.85 | +0.14% |
| 24-05-30 | 96.71 | +0.18% |
| 24-05-29 | 96.54 | -0.13% |
| 24-05-28 | 96.67 | -0.27% |
| 24-05-27 | 96.93 | +0.05% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:48 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU229E |
| ISIN | DE000SU229E2 |
| Date issued | 2023-12-01 |
| Maturity | 2024-12-20 (203 Days) |
| Parity | 1 : 1 |
| Emission price | 90.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 97 € |
|---|---|
| Lowest since issue | 88.75 € |
| Spread | 0.11 € |
| Spread % | 0.11% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
